SCHEMBL6798906

SCHEMBL6798906

C[C@H](CNC(=O)OC(C)(C)C)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
SYK P43405 1/20 0.37
SERPINE1 P05121 1/20 0.37
PCSK9 Q8NBP7 1/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 2/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
GFER P55789 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TSHR P16473 1/20 0.33
HCRTR2 O43614 1/20 0.33
MALT1 Q9UDY8 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5257223 1.00 L3MBTL1 (0.38) L3MBTL1SYKSERPINE1PCSK9KMT2A
SCHEMBL20276637 0.88 KMT2A (0.39) L3MBTL1SYKSERPINE1PCSK9KMT2A
SCHEMBL11632674 0.86 L3MBTL1 (0.38) L3MBTL1SYKSERPINE1PCSK9KMT2A
SCHEMBL11632667 0.86 L3MBTL1 (0.38) L3MBTL1SYKSERPINE1PCSK9KMT2A
SCHEMBL880771 0.84 KMT2A (0.37) L3MBTL1SYKSERPINE1PCSK9KMT2A
SCHEMBL18226807 0.84 CTSS (0.40) L3MBTL1SYKSERPINE1KMT2AALDH1A1
SCHEMBL18226806 0.84 CTSS (0.40) L3MBTL1SYKSERPINE1KMT2AALDH1A1
SCHEMBL18221182 0.84 MEN1 (0.46) KMT2AMEN1GAATDP1CA1
SCHEMBL17227817 0.84 MEN1 (0.46) KMT2AMEN1GAATDP1CA1
SCHEMBL29583631 0.82 L3MBTL1 (0.36) L3MBTL1SYKSERPINE1PCSK9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747021-B2 ANTICARCINOGENIC AGENT WITH LOW TOXICITY ELI LILLY AND COMPANY 2004-06-08 US disclosed
US-20020065261-A1 Anticarcinogenic agent with low toxicity UNIVERSITY OF HAWAII 2002-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065261-A1 Anticarcinogenic agent with low toxicity HCCS, TP53, GSTA1 L3MBTL1 1203/4885SYK 4757/4885SERPINE1 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.